Ascendis Pharma A/S (ASND) Expected to Post Quarterly Sales of $580,000.00
Brokerages forecast that Ascendis Pharma A/S (NASDAQ:ASND) will post sales of $580,000.00 for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Ascendis Pharma A/S’s earnings, with estimates ranging from $50,000.00 to $1.16 million. Ascendis Pharma A/S posted sales of $1.13 million during the same quarter last year, which suggests a negative year over year growth rate of 48.7%. The business is scheduled to issue its next earnings report on Wednesday, March 28th.
According to Zacks, analysts expect that Ascendis Pharma A/S will report full year sales of $580,000.00 for the current year, with estimates ranging from $1.97 million to $2.07 million. For the next year, analysts expect that the company will post sales of $1.70 million per share, with estimates ranging from $940,000.00 to $2.14 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Ascendis Pharma A/S.
A number of analysts have commented on ASND shares. Credit Suisse Group reiterated a “buy” rating and set a $50.00 target price on shares of Ascendis Pharma A/S in a research report on Sunday, February 25th. JPMorgan Chase & Co. set a $50.00 target price on Ascendis Pharma A/S and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Bank of America decreased their target price on Ascendis Pharma A/S from $46.00 to $43.00 and set a “buy” rating on the stock in a research report on Friday, November 17th. Zacks Investment Research downgraded Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Finally, BidaskClub upgraded Ascendis Pharma A/S from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 25th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Ascendis Pharma A/S currently has a consensus rating of “Buy” and an average price target of $52.67.
Ascendis Pharma A/S (NASDAQ ASND) traded up $2.35 on Friday, reaching $68.34. The company’s stock had a trading volume of 444,592 shares, compared to its average volume of 223,747. The stock has a market capitalization of $2,399.79, a P/E ratio of -18.70 and a beta of 0.68. Ascendis Pharma A/S has a one year low of $21.95 and a one year high of $69.00.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.